InvestorsHub Logo
Followers 828
Posts 119581
Boards Moderated 14
Alias Born 09/05/2002

Re: biopearl post# 12420

Thursday, 08/28/2014 5:30:03 PM

Thursday, August 28, 2014 5:30:03 PM

Post# of 20689
The Orange Book patents protecting 40mg Copaxone may fail to attain the non-obviousness threshold. If Teva believes that these patents are weak, they may settle with some or all of the Paragraph-IV challengers.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”